Search results
The Rev. Jeffrey Jackson: Cover anti-obesity drugs for older people in Wisconsin
Wisconsin State Journal· 6 hours agoAs a Middleton alderman and reverend, one of the issues I hear most from my neighbors and...
Insured patients often save less with Mark Cuban's drug company: Study
Becker’s Hospital Review· 6 days ago"Savings varied substantially by health insurance type, with uninsured patients achieving the greatest benefit," the researchers wrote. "Promoting transparent cost-plus pharmacy ...
Gateway - Quartz
Quartz· 6 days agoAfter dominating the market for weight loss drugs, Ozempic maker Novo Nordisk has set its sights on tackling treatments for heart disease next. Cardior, a Germany-based drug maker, develops ...
JD Supra: The ACA 1557 Final Regulations: Plans and Plan Sponsors as Covered Entities
JD Supra· 3 days agoIn a recent On the Subject (available here), we reported on the impact of the final rule (final rule) interpreting Section 1557 of the Affordable Care Act ...
Santa Claus concerned about the surging cost of weight-loss drugs: He's not the only one
Worcester Telegram & Gazette via Yahoo News· 3 days agoMedicare ever covered these drugs across the board. The scenario comes from the Health Policy...
Gateway - Quartz
Quartz· 6 days agoNovo Nordisk, the maker of the mega-popular diabetes and weight loss medications Ozempic and Wegovy, is set to report its first quarter earnings on May 2. The Danish pharma ...
Letter: We need alternatives to opioids
Bangor Daily News· 3 days agoAs a retired millworker, I have witnessed the devastating impactof the opioid crisis on mill towns throughout Maine and communities around the entire...
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
CNBC· 6 days agoSkyrocketing demand for a class of weight loss and diabetes treatments has lifted Eli Lilly to new...
US Drug Negotiations Plan Shifts Focus for Rare Disease Programs
Bloomberg Law· 7 days agoThe rare disease community is pushing for changes in the Inflation Reduction Act’s drug price-setting scheme as it leads more drugmakers and investors to reconsider development of< ...
